- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04532424
Transkraniel magnetisk stimulering til begrænset og gentagen adfærd ved ASD (TMS for ASD)
Investigating the efficacy of a form of TMS called theta-burst stimulation for restricted and repetitive behavior in ASD.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Briana Hernandez
- Telefonnummer: (650) 736-1235
- E-mail: autismdd@stanford.edu
Studiesteder
-
-
California
-
Stanford, California, Forenede Stater, 94305-5719
- Rekruttering
- Stanford University
-
Kontakt:
- Ryan Villacrucis
- Telefonnummer: (650) 736-1235
- E-mail: autismdd@stanford.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria.
- Diagnosis of Autism Spectrum Disorder (ASD)
- Meet criteria for Autism Spectrum Disorder (ASD) on clinical assessments (ADOS-2 or CARS if conducted remotely & ADI-R)
- Aged between 12-45 years old
- Have a reliable informant who can complete relevant questionnaires
- Have DARB scores which indicate high levels (50% or above) of RRB on one of the following domains: Insistence on Sameness, Obsessive Compulsive Behaviors, and Unusual Interests
Exclusion criteria.
- Any contraindications for TMS e.g. history of seizures other than clear substance-induced/fever-induced seizures with neurologist note or normal clean EEG and no seizure in at least 12 months prior to enrollment.
- Pregnancy.
- Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
- Active substance use (<1 week) or intoxication verified by toxicology screen--of cocaine, amphetamines, benzodiazepines.
- Showing symptoms of withdrawal from alcohol or benzodiazepines.
- DSM-5 diagnosis of bipolar disorder or a psychotic disorder e.g. schizophrenia.
- Significant sensory impairments such as blindness or deafness.
- Current severe insomnia (must sleep a minimum of 4 hours the night before stimulation).
- Not willing to cooperate with the TMS procedures.
- Currently taking Clozapine or another medication that the PI determines increases the risk of TMS or may disrupt the efficacy.
- A motor threshold that is too high to allow safe/tolerable treatment.
- Conditions that increase the risk for COVID-19 (in accordance with university guidelines).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Målrettet insisteren på ensartethed
|
Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine. |
|
Eksperimentel: Målretning af stereotyp motorisk adfærd
|
Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Repetitive Behavior Scale-Revised (RBS-R)
Tidsramme: Up to one month post-treatment
|
44-item parent-report questionnaire to measure restricted and repetitive behavior in ASD. We predict that each TMS target will selectively reduce the subscale being targeted. |
Up to one month post-treatment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Set-shifting performance (Dimensional Change Card Sort Test score)
Tidsramme: Baseline & immediately after treatment
|
The Dimensional Change Card Sort Test one of the cognitive measures from the NIH toolbox. These measures are administered on an iPad. The test takes 4 minutes to complete. |
Baseline & immediately after treatment
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Antonio Y. Hardan, MD, Stanford University
Publikationer og nyttige links
Generelle publikationer
- Oberman LM, Rotenberg A, Pascual-Leone A. Use of transcranial magnetic stimulation in autism spectrum disorders. J Autism Dev Disord. 2015 Feb;45(2):524-36. doi: 10.1007/s10803-013-1960-2.
- Barahona-Correa JB, Velosa A, Chainho A, Lopes R, Oliveira-Maia AJ. Repetitive Transcranial Magnetic Stimulation for Treatment of Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. Front Integr Neurosci. 2018 Jul 9;12:27. doi: 10.3389/fnint.2018.00027. eCollection 2018.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IRB-57738
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .